CA19-9 Levels and Survival in Pancreatic Cancer
Author Information
Author(s): Ko A H, Hwang J, Venook A P, Abbruzzese J L, Bergsland E K, Tempero M A
Primary Institution: University of California at San Francisco Comprehensive Cancer Center
Hypothesis
Does a decline in CA19-9 levels correlate with improved survival and treatment outcomes in patients with advanced pancreatic cancer receiving gemcitabine?
Conclusion
Declines in serum CA19-9 levels during treatment correlate with improved survival and time to treatment failure in patients with advanced pancreatic cancer.
Supporting Evidence
- Patients with >75% decline in CA19-9 had a median survival of 12.0 months.
- Patients with no decline in CA19-9 had a median survival of 4.3 months.
- 68.4% of patients achieved at least a 25% decline in CA19-9 during treatment.
- Statistically significant differences in survival were observed based on CA19-9 decline thresholds.
Takeaway
If a blood test shows that a certain marker (CA19-9) goes down during treatment for pancreatic cancer, it usually means the patient is doing better.
Methodology
This study pooled data from three clinical trials examining the effects of fixed-dose rate gemcitabine on CA19-9 levels and patient outcomes.
Potential Biases
Potential bias due to the inclusion of patients with only one CA19-9 measurement, as they were classified as nondecliners.
Limitations
The study's retrospective nature and lack of uniformity in lab methodology across different institutions may affect the results.
Participant Demographics
The study included 76 patients with advanced pancreatic cancer, predominantly with extrapancreatic metastases.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website